AIM ImmunoTech Inc (NYSE:AIM) has announced the promotion of Christopher McAleer from the company’s deputy scientific officer to the position of scientific officer.
The immuno-pharma firm said McAleer is an accomplished scientist with a diverse range of skills from general wet lab technique to company-wide operations management.
“Since bringing him on board in June as deputy science officer, Chris has been a valued member of the team and played an integral role in advancing our clinical development programs for Ampligen,” AIM ImmunoTech CEO Thomas Equels said in a statement.
READ: AIM ImmunoTech reports positive safety, tolerability, and biological activity data from Phase 1 Ampligen study
“We are pleased to deepen his role with his appointment as scientific officer as we continue to advance our pipeline forward,” Equels added.
AIM also noted that McAleer has held positions at Hesperos, Inc, where he helped to build a start-up biotech Contract Research Organization (CRO) from a three-employee, $500,000 per year operation to a 30-person, $5 million plus per year operation.
Ampligen, AIM’s lead product, is currently being used as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center, according to the company.
AIM ImmunoTech is an immuno-pharma company focused on researching and developing therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.
Contact Sean at sean@proactiveinvestors.com